Generalized Myasthenia Gravis clinical trials

Explore recruiting generalized myasthenia gravis clinical trials.

Recruiting generalized myasthenia gravis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Generalized Myasthenia Gravis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PHASE 2, RANDOMIZED, BLINDED, PLACEBOCONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (MAGIC)

Denmark, Poland, France, Netherlands, Norway, Italy +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patients with generalized myasthenia gravis, followed by an open-label extension phase.

Spain, Belgium, Netherlands, Poland, Romania, France +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, multi-center, phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis

France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study with an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients with Generalized Myasthenia Gravis

Italy, Belgium, France, Spain, Denmark, Poland +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A MULTICENTER, OPEN-LABEL, OUTPATIENT STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF A ZILUCOPLAN AUTO INJECTOR COMBINATION PRODUCT FOR SUBCUTANEOUS SELF-ADMINISTRATION BY STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Descartes-08 in Patients With Generalized Myasthenia Gravis (MG)

Italy, Spain, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Generalized Myasthenia Gravis trials by city

Generalized Myasthenia Gravis in Toronto Generalized Myasthenia Gravis in Vancouver Generalized Myasthenia Gravis in Montreal Generalized Myasthenia Gravis in Calgary Generalized Myasthenia Gravis in Edmonton Generalized Myasthenia Gravis in Ottawa Generalized Myasthenia Gravis in Winnipeg Generalized Myasthenia Gravis in Quebec City Generalized Myasthenia Gravis in Hamilton Generalized Myasthenia Gravis in Kitchener Generalized Myasthenia Gravis in London Generalized Myasthenia Gravis in Halifax Generalized Myasthenia Gravis in New York Generalized Myasthenia Gravis in Los Angeles Generalized Myasthenia Gravis in Chicago Generalized Myasthenia Gravis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease